Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet

Diabetologia

Volumn 45, Issue 9, 2002, Pages 1255-1262

  Yu, P ^a   Wang, M ^a   Deng, Y ^a   Fan, H ^a   Shira Bock, L ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Aminoguanidine; Atherosclerosis; Formaldehyde; Methylamine; Methylglyoxal; Semicarbazide sensitive amine oxidase (SSAO); SSAO inhibitor

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); AMINOGUANIDINE; BIOLOGICAL MARKER; FORMALDEHYDE; MALONALDEHYDE; METHYGLOXAL; METHYLAMINE; MOFEGILINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DEAMINATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HYPOTHESIS; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION; URINE LEVEL; VASCULAR LESION;

ALBUMINURIA; ALLYL COMPOUNDS; AMINE OXIDASE (COPPER-CONTAINING); AMINES; ANIMALS; ARTERIOSCLEROSIS; BUTYLAMINES; CHOLESTEROL, DIETARY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GUANIDINES; METHYLAMINES; MICE; MICE, INBRED STRAINS;

EID: 0036383451     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0903-9     Document Type: Article

References (47)

1. Nilsson S-E, Tryding N, Tufvesson G (1968) Serum mono-amine oxidase in diabetes mellitus and some other internal diseases. Acta Med Scand 184:105-108
2. Yuen C-T, Easton D, Misch K, Rhodes E (1987) Increased activity of serum amine oxidase in granuloma annulare, necrobiosis lipoidics and diabetes. Br J Dermatol 11:643-649
3. Boomsma F, Meiracker A-H van den, Winkel S et al. (1999) Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia 42:233-237
4. Hayes B-E, Clarke D-E (1990) Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res Commun Chem Pathol Pharmacol 69:71-83
5. Elliott J, Fowden A-L, Callingham B-A, Sharman D-F, Silver M (1991) Physiological and pathological influences on sheep blood plasma amine oxidase: Effect of pregnancy and experimental alloxan-induced diabetes mellitus. Res Vet Sci 50:334-339
6. Garpenstrand H, Ekblom J, Backlund L-B, Oreland L, Rosenqvist U (1999) Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diabet Med 16:514-521
7. Boomsma F, Veldhuisen D-J van, Kam P-J de et al. (1997) Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 33:387-391
8. Ishizaki F (1990) Plasma benzylamine oxidase activity in cerebrovascular disease. Eur Neurol 30:104-107
9. Mészáros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K (1999) Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with BMI and serum triglyceride. Metabolism 48:113-117
10. Boomsma F, De Lam P-J, Tjeerdsma G, Van den Meiracker A-H, Van Veldhuisen D-J (2000) Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 21:1859-1863
11. Yu P-H (2000) Semicarbazide-sensitive amine oxidase (SSAO) and mortality in chronic heart failure. Eur Heart J 21:1812-1814
12. Buffoni F (1995) Semicarbazide-sensitive amine oxidase: some biochemical properties and general consideration. Prog Brain Res 106:323-331
13. Yu P-H (1990) Deamination of aliphatic amines of different chain lengths by rat aorta semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 42:882-884
14. Lyles G-A, Chalmers J (1992) The metabolism of amino-acetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 31:1417-1424
15. Callingham B-A, Crosbie A-E, Rous B-A (1995) Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Prog Brain Res 106:305-321
16. Yu P-H (1998) Deamination of methylamine and angiopathy; toxicity of formaldehyde, oxidative stress and relevance to protein glycoxidation in diabetes. J Neural Transm 52 [Suppl]:201-216
17. Yu P-H, Zuo D-M (1993) Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells; possible consequence for diabetes. Diabetes 42:594-603
18. Deng Y-L, Boomsma F, Yu P-H (1998) Deamination of methylamine and aminoacetone increases aldehydes and oxidative stress in rats. Life Sci 63:2049-2058
19. Yu P-H, Zuo D-M (1996) Formaldehyde produced endogenously via deamination of methylamine; a potential risk factor for initiation of endothelial injury. Atherosclerosis 120:189-197
20. Yu P-H, Zuo D-M (1997) Aminoguanidine inhibits semi-carbazide-sensitive amine oxidase activity; implication for advanced glycation and angiopathy in diabetes. Diabetologia 363:1243-1250
21. Jones D-J, Burnett P-C (1975) Creatine metabolism and toxicity. Kidney Int 7:S294-S298
22. Yu P-H, Dyck R-F (1998) Impairment of methylamine clearance in uremic patients and its nephropathological implications. Clin Nephrol 49:299-302
23. Siracusa L-D (1994) Theagouti gene: turned on to yellow. Trends Genet 10:423-428
24. Hayase M, Yoshihiro O, Katsuura G, Shintaku H, Hosoda K, Nakao K (1996) Regulation of obese gene expression in KK mice and congenic lethal yellow obese KKAy mice. Am J Physiol 271:E333-E339
25. Iwatsuka H, Shino A, Suzuoki Z (1970) General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17:23-35
26. Wehner H, Hohn D, Faix-Schade U, Huber H, Walzer P (1972) Glomerular changes in mice with spontaneous hereditary diabetes. Lab Invest 27:331-340
27. Deng Y-L, Yu P-H (1999) Simultaneous determination of formaldehyde and methylglyoxal in urine; involvement of deamination of methylamine in diabetic complication. J Chromatogr Sci 37:317-322
28. Tietz N-W (1982) Fundamentals of clinical chemistry. Saunders, Philadelphia, pp 994-999
29. Fielding B-A, Price D-A, Houlton C-A (1983) Enzyme immunoassay for urinary albumin. Clin Chem 29:355-357
30. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P-A (1985) Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57:65-73
31. Yu P-H, Zuo D-M (1991) (E)-4-Fluoro-beta-fluoroethylene benzene butamine (MDL-72974A) as a highly potent inhibitor for semicarbazide-sensitive amine oxidase from vascular tissues and serum of different species. Biochem Pharmacol 43:307-312
32. Yu P-H, Deng Y-L (2000) Potential cytotoxic effect of chronic administration of creatine, a nutrition supplement to augment athletic performance. Med Hypotheses 54:726-728
33. Yu P-H, Deng Y-L (1998) Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: Involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover. Atherosclerosis 140:357-363
34. Zreika M, Fozard J-R, Dudley M-W, Bey P, McDonald I-A, Palfreyman M-G (1989) MDL 72974; A potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J Neural Transm 1:243-254
35. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial protein cross-linking. Science 232:1629-1632
36. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558
37. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes 40:1328-1334
38. Kagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K, Nagai K (1992) Effect of aminoguanidine on functional and structural in peripheral nerve of STZ-induced diabetic rats diabetes. Diabetes 41:47-52
39. Panagiotopoulos S, O'Brien R-C, Bucala R, Cooper M-E, Jerums G (1998) Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 136: 125-131
40. Boomsma F, van-Dijk J, Bhaggoe U-M, Bouhuizen A-M, Meiracker A-H van den (2000) Variation in semicarbazide-sensitive amine oxidase activity in plasma and tissues of mammals. Comp Biochem Physiol C Toxicol Pharmacol 126:69-78
41. Haffner S-M, Stern M-P, Gruber M-K, Hazuda H-P, Mitchell B-D, Patterson J-K (1990) Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727-731
42. Edelstein D, Brownlee M (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29
43. McLellan A-C, Phillips S-A, Thornalley P-J (1992) The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. Anal Biochem 206:17-23
44. Slatter D-A, Bolton C-H, Bailey A-J (2000) The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 43:550-557
45. Gallaher D-D, Csallany A-S, Shoeman D-W, Olson J-M (1993) Diabetes increases excretion of urinary malonaldehyde conjugates in rats. Lipids 28:663-666
46. Lo T-W, Selwood T, Thornalley P-J (1994) The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol 48:1865-1870
47. Helander A, Tottmar O (1987) Metabolism of biogenic aldehydes in isolated human blood cells, platelets and in plasma. Biochem Pharmacol 36:1077-1082